



This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Autoimmune dise	ase			
Systemic lupus erythematosus (SLE), arthritis and certain other autoimmune diseases	Fc-γ receptor IIb (CD32B)	A study in mice suggests that increasing the expression of CD32B on B cells might help treat autoimmune disease. In mouse models of collagen-induced arthritis (CIA), CD32B overexpression on B cells significantly reduced late-stage disease severity compared with that in control animals with normal expression of CD32B ( <i>p</i> <0.05). When CD32B was overexpressed on B cells in SLE mouse models, 85% of the transgenic mice survived at 34 weeks compared with none of the wild-type mice ( <i>p</i> <0.0001). In contrast, macrophage-specific overexpression of CD32B increased mortality in the mouse models after infection with <i>Streptococcus pneumoniae</i> . The researchers are examining the expression of CD32B in patients with various autoimmune diseases. SuppreMol GmbH's SM101 soluble form of CD32B is in preclinical testing to treat the autoimmune disease idiopathic thrombocytopenic purpura (ITP).	Not applicable	Brownlie, R. et al. J. Exp. Med.; published online March 24, 2008; doi:10.1084/jem.20072565  Contact: Kenneth G.C. Smith, University of Cambridge School of Clinical Medicine, Cambridge, U.K. e-mail: kgcs2@cam.ac.uk